Results 141 to 150 of about 170,023 (183)

Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial. [PDF]

J Neurol
Kappos L, Edan G, Freedman MS, Hartung HP, Montalbán X, Barkhof F, Koelbach R, MacManus DG, Wicklein EM, BENEFIT and BENEFIT 15 Study Groups.   +9 more
europepmc   +1 more source

Molecular cloning and characterization of interferon alpha/beta response element binding factors of the murine (2'-5')oligoadenylate synthetase ME-12 gene.

, 1991
Cong Yan, Igor Tamm
openalex   +2 more sources

Policy networks in healthcare policy: a case study on the National Institute for Clinical Excellence and the appraisal for beta-interferon treatment for patients with multiple sclerosis [PDF]

, 2016
Theodora Kostikou
openalex  

Thrombotic Microangiopathy after a 15-year Treatment with Interferon Beta-1b in a Patient with Multiple Sclerosis: A Case Report and Review of Literature. [PDF]

Intern Med
Akita S, Fujibayashi K, Ueno EI, Wakasa M, Kawai Y, Kajinami K.   +5 more
europepmc   +1 more source

Immunomodulatory mechanisms of interferon beta in patients with multiple sclerosis

, 2011
Silva Marković-Pleše
openalex  

Cloning and Functional Characterization of Novel Human Neutralizing Anti-IFN-α and Anti-IFN-β Antibodies. [PDF]

J Immunol
Papasavvas E, Lu L, Fair M, Oliva I, Cassel J, Majumdar S, Mounzer K, Kostman JR, Tebas P, Bar-Or A, Muthumani K, Montaner LJ.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Interaction of PEGylated interferon-beta with antibodies to recombinant interferon-beta

International Immunopharmacology, 2018
Because PEGylated molecules exhibit different physicochemical properties from those of the parent molecules, PEGylated interferonβ-1a (pegIFNβ-1a) may be able to be used with retained bioactivity in Multiple Sclerosis (MS) patients who have previously developed neutralizing antibodies (NABs) to recombinant interferonβ (rIFNβ).
Francesca, Gilli, Adrianna L, De La Torre, Darlene B, Royce, Andrew R, Pachner   +3 more
openaire   +2 more sources

Interferon Beta-1a

Hospital Pharmacy, 2002
Each month, subscribers to The Formulary® Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada, Terri Levien, Danial E. Baker   +2 more
openaire   +1 more source

Interferon beta in multiple sclerosis

Neurology, 1993
Interferon beta 1B (IFNbeta1b) lessens multiple sclerosis (MS) attack frequency and accumulating disease burden as assessed by MRI. The agent is an immune system modulator. The immune response in MS is thought to involve a delayed-type hypersensitivity (DTH) response mediated by Th1 type T cells. IFNbeta1b lessens expression of MHC-class II proteins on
openaire   +2 more sources